Jpmorgan Chase & CO Astria Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ATXS
# of Institutions
104Shares Held
49.4MCall Options Held
27.6KPut Options Held
29.7K-
Perceptive Advisors LLC New York, NY6.49MShares$74.3 Million1.71% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.04MShares$57.8 Million0.69% of portfolio
-
Vr Adviser, LLC New York, NY3.61MShares$41.3 Million3.6% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$40.7 Million6.42% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$40.3 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $174M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...